Satri-cel ushers CAR T into solid tumors, but not on the modality’s usual terms

CARsgen’s satri-cel shows that CAR T therapy can deliver meaningful benefit in gastric cancer even without reproducing the broad, durable responses that have defined its use in blood cancers. As the first CAR T approved for a solid tumor, satri-cel provides an early benchmark for the modality: clinically meaningful disease control, leaving next-generation designs to test how much further efficacy can improve.

That profile now sets up the first market test of how physicians, patients, and payers will weigh CAR T’s cost, complexity, and safety burden against solid tumor efficacy centered more on disease control rather than durable remission...